Senti Biosciences(SNTI)
$0.14-0.01 (-4.76%)
SNTI
Senti Biosciences stock drug pipeline
$0.14
At close:-0.01 (-4.76%)
Want to see SNTI full AI Analyst Report?
Senti Biosciences (SNTI) Drug Pipeline
270 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Senti-202 | Aml/Mds, Cd33 Expressing Hematological Malignancies, Flt3 Expressing Hematological Malignancies | Phase I | Recruiting | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Mar 13, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Senti-202 | Phase I | Aml/Mds, Cd33 Expressing Hematological Malignancies, Flt3 Expressing Hematological Malignancies | Recruiting | SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS | Mar 13, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Senti Biosciences, Inc. (SNTI) have in its pipeline
Senti Biosciences SNTI is currently developing the following drugs: Senti-202. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

